Leading India-based Investigator Sites Now Available on goBalto.com
SAN FRANCISCO, CA – May 19, 2009 – goBalto, an online drug development partnering site for the pharmaceutical development and drug manufacturing industry, announced today that Maya Clinicals is making its proprietary list of India-based Investigator Sites and hospitals available on goBalto.com.
Maya Clinicals is a leading Clinical Research Organization (CRO) in India, one of the foremost countries for clinical trials outsourcing. Its proprietary list of Investigator Sites listed on goBalto is divided into two categories: “Sourced by Maya Clinicals” and “Screened by Maya Clinicals.” “Sourced by” indicates Maya Clinicals has identified these Investigator Sites as actively operating in India and maintains information on the company. “Screened by” indicates Maya Clinicals has visited the facility, met with senior management and reviewed the company’s specific capabilities.
Since launching in April, goBalto has acquired over 2,000 members who represent, research, manufacturing and procurement professionals from leading pharmaceutical and biotech organizations from all over the world.
According to a recent PricewaterhouseCoopers study, the CRO market in India was $323 million in 2007. Largely driven by outsourcing from international firms, it is projected to grow at an estimated 49 percent annually, bringing the market to nearly $900 million in 2010. The global CRO market is growing at a far slower 12.6 percent per year.
“Acquiring Maya Clinicals’ proprietary list is a great opportunity for the goBalto community,” said Jae Chung, founder and CEO, goBalto. “Unless you’ve been actively conducting trials, it is quite challenging for drug development professionals, unfamiliar with India’s outsourcing industry, to find qualified Investigator Sites there. By interfacing Maya Clinicals’ list to our platform, users will be able to more quickly and easily evaluate the leading Investigator Sites in the region and become informed about the exciting, high-growth Indian market.”
“We were delighted to see goBalto launch its drug development partnering platform last month and to observe its initial rapid growth,” said Mahdav Reddy, President of Maya Clinicals. “Over the past five years we have gathered an extensive network of hospitals, principal investigators and CRAs for Phase I and Phase IV clinical trials. Our partnership with goBalto will help them extend and deepen their reach with pharmaceutical and biotech companies.”
Maya Clinicals’ list adds India-based Investigator Sites to the list of over 7,000 potential service providers goBalto has assembled and profiled based on technical expertise, facilities, commercial terms and quality. The goBalto platform allows users to rate companies, post comments to vendors and evaluate service providers